Alliance Pharma plc (AIM:APH) acquired ScarAway and Kelo-cote from Perrigo Company plc (NYSE:PRGO) for $19.4 million on March 25, 2022. Consideration was funded from existing cash and debt resources. ScarAway and Kelo-cote, generated combined EBITDA of $2 million in the 12 months to 28 February 2022. Freddie Barnfield, Duncan Monteith and James Black of Numis Securities Limited and Daniel Adams and Patrick Robb of Investec Bank plc acted as financial advisors to Alliance Pharma plc. Cahill Gordon & Reindel LLP acted as legal advisor to Perrigo Company plc in the transaction.

Alliance Pharma plc (AIM:APH) completed the acquisition of ScarAway and Kelo-cote from Perrigo Company plc (NYSE:PRGO) for $19.4 million on March 25, 2022.